ATE530181T1 - Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel - Google Patents
Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangelInfo
- Publication number
- ATE530181T1 ATE530181T1 AT07724008T AT07724008T ATE530181T1 AT E530181 T1 ATE530181 T1 AT E530181T1 AT 07724008 T AT07724008 T AT 07724008T AT 07724008 T AT07724008 T AT 07724008T AT E530181 T1 ATE530181 T1 AT E530181T1
- Authority
- AT
- Austria
- Prior art keywords
- prophylaxis
- treatment
- ynylamin
- omigapil
- oxepin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007217A EP1842539A1 (de) | 2006-04-05 | 2006-04-05 | Verwendung von N-(dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung und/oder Behandlung von angeborener Muskeldystrophie oder Myopathie verursacht durch einen Kollagen IV Mangel |
| PCT/EP2007/003067 WO2007115776A1 (en) | 2006-04-05 | 2007-04-04 | USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530181T1 true ATE530181T1 (de) | 2011-11-15 |
Family
ID=36190429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07724008T ATE530181T1 (de) | 2006-04-05 | 2007-04-04 | Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7875648B2 (de) |
| EP (2) | EP1842539A1 (de) |
| JP (1) | JP4972156B2 (de) |
| AT (1) | ATE530181T1 (de) |
| AU (1) | AU2007236161B2 (de) |
| CA (1) | CA2648155C (de) |
| CY (1) | CY1112132T1 (de) |
| DK (1) | DK2004176T3 (de) |
| ES (1) | ES2371627T3 (de) |
| MX (1) | MX2008012867A (de) |
| NZ (1) | NZ571129A (de) |
| PL (1) | PL2004176T3 (de) |
| PT (1) | PT2004176E (de) |
| SI (1) | SI2004176T1 (de) |
| WO (1) | WO2007115776A1 (de) |
| ZA (1) | ZA200807800B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1757284A1 (de) * | 2005-08-25 | 2007-02-28 | Santhera Pharmaceuticals (Schweiz) AG | Verwendung von N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung oder Behandlung der Muskulardystrophy |
| WO2014120885A1 (en) | 2013-01-30 | 2014-08-07 | The Johns Hopkins University | Treatment of drug abuse by preventing gapdh nitrosylation |
| EP4351545A1 (de) | 2021-06-07 | 2024-04-17 | Katholieke Universiteit Leuven | Idebenon zur behandlung von arzneimittelresistenter epilepsie |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780244A (en) | 1993-09-27 | 1998-07-14 | La Jolla Cancer Research Foundation | Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy |
| US5863743A (en) | 1994-08-12 | 1999-01-26 | University Of Iowa Research Foundation | Merosin deficiency-type congenital muscular dystrophy |
| ATE203528T1 (de) | 1995-02-08 | 2001-08-15 | Novartis Erfind Verwalt Gmbh | Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine |
| AR008371A1 (es) * | 1996-05-30 | 2000-01-19 | Novartis Ag | Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ |
| US7078379B2 (en) | 2002-06-03 | 2006-07-18 | Santhera Pharmaceuticals (Schweiz) Gmbh | Treatment of congenital muscular dystrophies |
| EP1589963A1 (de) | 2003-01-29 | 2005-11-02 | Novartis AG | Verwendung von10-aminoaliphatyl-diben[b,f]oxepinen für die behandlung von degenerativenaugenkrankheiten |
| AR046320A1 (es) | 2003-11-06 | 2005-11-30 | Novartis Ag | Composiciones farmaceuticas estabilizadas de dibenzo-oxepina. |
| EP1757284A1 (de) * | 2005-08-25 | 2007-02-28 | Santhera Pharmaceuticals (Schweiz) AG | Verwendung von N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung oder Behandlung der Muskulardystrophy |
-
2006
- 2006-04-05 EP EP06007217A patent/EP1842539A1/de not_active Withdrawn
-
2007
- 2007-04-04 NZ NZ571129A patent/NZ571129A/en not_active IP Right Cessation
- 2007-04-04 JP JP2009503488A patent/JP4972156B2/ja not_active Expired - Fee Related
- 2007-04-04 DK DK07724008.3T patent/DK2004176T3/da active
- 2007-04-04 MX MX2008012867A patent/MX2008012867A/es active IP Right Grant
- 2007-04-04 CA CA2648155A patent/CA2648155C/en not_active Expired - Fee Related
- 2007-04-04 AT AT07724008T patent/ATE530181T1/de active
- 2007-04-04 PT PT07724008T patent/PT2004176E/pt unknown
- 2007-04-04 AU AU2007236161A patent/AU2007236161B2/en not_active Ceased
- 2007-04-04 EP EP07724008A patent/EP2004176B1/de active Active
- 2007-04-04 US US12/295,801 patent/US7875648B2/en not_active Expired - Fee Related
- 2007-04-04 PL PL07724008T patent/PL2004176T3/pl unknown
- 2007-04-04 SI SI200730799T patent/SI2004176T1/sl unknown
- 2007-04-04 WO PCT/EP2007/003067 patent/WO2007115776A1/en active Application Filing
- 2007-04-04 ES ES07724008T patent/ES2371627T3/es active Active
-
2008
- 2008-09-10 ZA ZA200807800A patent/ZA200807800B/xx unknown
-
2011
- 2011-11-30 CY CY20111101180T patent/CY1112132T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112132T1 (el) | 2015-11-04 |
| AU2007236161A1 (en) | 2007-10-18 |
| JP4972156B2 (ja) | 2012-07-11 |
| WO2007115776A1 (en) | 2007-10-18 |
| NZ571129A (en) | 2011-01-28 |
| PT2004176E (pt) | 2011-11-23 |
| US20090176867A1 (en) | 2009-07-09 |
| EP1842539A1 (de) | 2007-10-10 |
| CA2648155A1 (en) | 2007-10-18 |
| JP2009532404A (ja) | 2009-09-10 |
| ZA200807800B (en) | 2009-06-24 |
| EP2004176B1 (de) | 2011-10-26 |
| DK2004176T3 (da) | 2012-02-06 |
| AU2007236161B2 (en) | 2009-12-10 |
| SI2004176T1 (sl) | 2012-01-31 |
| PL2004176T3 (pl) | 2012-03-30 |
| EP2004176A1 (de) | 2008-12-24 |
| ES2371627T3 (es) | 2012-01-05 |
| CA2648155C (en) | 2011-11-15 |
| US7875648B2 (en) | 2011-01-25 |
| MX2008012867A (es) | 2008-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
| IN2012DN01233A (de) | ||
| NZ596579A (en) | Bace inhibitors | |
| BR112012026948A2 (pt) | composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose. | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
| EA201170922A1 (ru) | Производные сульфонамида | |
| EA201270505A1 (ru) | Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| CY1112284T1 (el) | Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων | |
| MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
| NO20084328L (no) | Nye forbindelser | |
| ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| CY1112233T1 (el) | Παραγωγα 1,2,3-τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| TW200626158A (en) | Naphthaline derivatives | |
| IL193252A0 (en) | N-hydroxyacrylamide compounds | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| EA201100872A1 (ru) | Производные хиназолинамида | |
| DE602005018390D1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| ATE530181T1 (de) | Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2004176 Country of ref document: EP |